Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Contineum Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
50
0
Research and development
27.6
38.4
51.5
General and administrative
6.32
12.5
16.5
Operating expenses
33.9
50.9
68.1
Operating income
16.1
-50.9
-68.1
Interest expense
0.21
0
Interest income
4.61
8.91
8.25
Other non-operating income
7.09
8.64
8.08
Pre-tax income
23.2
-42.3
-60.1
Income tax
0.45
0
0
Net income
22.7
-42.3
-60
EBITDA
16.3
-50.6
-67.7
EPS, basic
1.36
-2.18
-2.17
EPS, diluted
0.08
-2.18
-2.17
Shares, basic (weighted)
2.31
19.4
27.7
Shares, diluted (weighted)
3.4
19.4
27.7
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
15.5
21.9
75.6
Short-term investments
110
183
187
Other current assets
2.52
1.63
5.02
Total current assets
128
206
268
Property, plant and equipment
0.68
0.99
0.83
Lease right-of-use assets
0.72
5.47
7.64
Other non-current assets
1.28
0
0.26
Total assets
130
213
277
Accounts payable
0.64
1.81
1.02
Accrued liabilities
4.39
6.71
6.39
Total current liabilities
5.48
9.97
9.74
Lease liabilities
0.11
4.81
5.91
Other non-current liabilities
0.11
0
Total liabilities
5.7
14.8
15.7
Paid-in capital
7.1
315
438
Retained earnings
-75.1
-117
-177
Other comprehensive income
0.11
0.07
0.26
Shareholders' equity
-67.9
198
261
Total equity
-67.9
198
261
Total liabilities and equity
130
213
277
Shares outstanding
2.35
Cash flow statement
FY2024
FY2024
FY2025
Net income
22.7
-42.3
-60
Depreciation and amortization
0.2
0.26
0.32
Stock-based compensation
2.22
6.8
10
Change in payables
0
1.14
-0.87
Cash from operations
19.3
-32.8
-55.3
Capital expenditures
-0.41
-0.51
-0.23
Purchases of investments
-142
-226
-163
Sales and maturities of investments
76.7
157
159
Cash from investing
-65.6
-69.7
-3.71
Debt repaid
-3.75
0
Stock issued
0
108
0.22
Share buybacks
-0.03
0
Cash from financing
56.2
109
113
Net change in cash
9.96
6.42
53.7
Free cash flow
18.9
-33.4
-55.5
Interest paid
0.15
0
Income taxes paid
0.45
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.56 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-25.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-24.7%
Net income / average total assets.
Return on invested capital (ROIC)
-33.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
31.8%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
30.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
43.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
31.1x
Current assets / current liabilities.
Quick ratio
30.5x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
30.5x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.36
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.35
Cash from operations / diluted weighted shares.
Book value per share
$6.39
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.62x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.62x
Market cap / tangible book value, when positive.
FCF yield
-13.1%
Free cash flow / market cap.
Earnings yield
-16.0%
Net income / market cap (the inverse of P/E).
Was Contineum Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $60.0M.
How much free cash flow did Contineum Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $55.3M minus capital expenditures of $231.0K left free cash flow of -$55.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.